News >

Immunotherapy Research Key to Moving SCLC Field Forward

Brandon Scalea
Published: Tuesday, Oct 23, 2018

Ramsey N. Asmar, MD

Ramsey N. Asmar, MD

The addition of atezolizumab (Tecentriq) to chemotherapy for the frontline treatment of patients with extensive-stage small cell lung cancer (SCLC) significantly prolonged progression-free (PFS) and overall survival (OS) compared with chemotherapy alone, according to phase III data of the IMpower133 trial.

In the study, 403 patients with treatment-naïve SCLC were randomized to receive atezolizumab (n = 201) or placebo (n = 202). At a median follow-up of 13.9 months, the median OS in the atezolizumab group was 12.3 months versus 10.3 months for chemotherapy alone (HR, 0.70; 95% CI, 0.54-0.91; P = .007). Moreover, median PFS was 5.2 months for patients treated with the combination and 4.3 months in the placebo group. 

Patients received carboplatin and etoposide with either atezolizumab or placebo for 4 induction cycles of 21 days, followed by a maintenance phase of the PD-L1 inhibitor or placebo. 

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication